Success Stories: NAILG Guided Associate Research Scientist in Synthetic Organic Chemistry From NIW to EB-1A Approval

Client’s Testimonial:

“Thank you all for your sincere efforts and unwavering support throughout this journey. It wouldn’t have been possible without your dedication. It has truly been a pleasure working with each of you.”

On October 20^th, 2023, and May 12^th, 2025, we received another EB-2 NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approvals for an Associate Research Scientist in the Field of Synthetic Organic Chemistry (Approval Notice).

General Field: Synthetic Organic Chemistry

Position at the Time of Case Filing: Associate Research Scientist

Country of Origin: India

State of Residence at the Time of Filing: Indiana

Approval Notice Date: : October 20^th, 2023 (NIW) and May 12^th, 2025 (EB1A)

Processing Time: 25 days (NIW) (Premium Processing Requested), and 1 year, 2 months, 26 days (EB1A)

Case Summary:

Our client is a recognized authority in synthetic organic chemistry, specializing in the development of small-molecule ligands with applications in drug discovery and pharmaceutical development. His research has significantly contributed to the advancement of anti-diabetic and anti-cancer compounds, as well as the design of FAP-targeted ligands. His work stands at the forefront of pharmaceutical innovation, directly impacting the vitality of the pharmaceutical industry and improving human health.

Over the years, he has made original contributions of major significance in synthetic chemistry, with research that includes:

❖ Advancement of Dye-sensitized Solar Cells (DSSCs) for more efficient energy generation

❖ Development of modified constituents to generate anti-diabetic and anti-cancer compounds

❖ The introduction of novel constituents to build biologically significant compounds

❖ Design of FAP-targeted ligands with potential therapeutic applications

His academic output is a testament to his leadership in the field:

● 13 peer-reviewed scientific articles, including 4 first-authored, 4 abstracts, and 1 preprint
● 6 patent applications for innovative chemical compounds and methodologies
● Publications cited in at least 27 countries and 207 citations, solidifying his place as a leading contributor to synthetic organic chemistry.
● At least 40 peer reviews further establish his standing as a respected authority within the scientific community.

One expert remarked in their recommendation:

“[Client] is working in an area of great importance, as drug discovery and development are foundational to the vitality of the pharmaceutical industry and, more importantly, to human wellbeing. On a personal note, [client] is one of the hardest-working and reliable scientists I have personally observed; it was my great fortune to have collaborated closely with him for our time together at Purdue. Considering the merits of his research in conjunction with his broader contributions to the field, [client] has clearly established himself at the forefront of the field of synthetic organic chemistry.”

North America Immigration Law Group (NAILG) worked closely with him throughout his NIW and EB-1A petitions, ensuring his exceptional achievements were clearly demonstrated. After initially receiving an NIW approval, NAILG helped transition our client to the EB-1A petition process, where our team highlighted not only his academic excellence but also the national relevance of his contributions to pharmaceutical innovation and human health. With careful planning and strategic submission, NAILG ensured the petition was strong and compelling, leading to EB-1A approval without delays.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.